Cardiac Contractility Modulation Therapy in Amyloid Cardiomyopathy Patients With Heart Failure

Launched by OSPEDALE C & G MAZZONI · Dec 21, 2021

Keywords

ClinConnect Summary

Amyloidosis represents a group of human degenerative diseases characterized by the deposition of aggregates of abnormally folded proteins in single or multi-organs. Cardiac amyloidosis is primarily associated with the systemic production and release of a number of amyloidogenic proteins, notably immunoglobulin light chain proteins (also known as amyloid light chain or AL) or transthyretin proteins (TTR). Notably, although myocardial dysfunction is generally understood as a result of infiltration by extracellular amyloid deposits, there is experimental evidence of direct cytotoxic effect, po...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older
• • Male or a nonpregnant female
• • All of the following: Established diagnosis of amyloid TTR Cardiomyopathy; baseline ejection fraction ≥25% and ≤45%; at least one hospitalization due to worsening heart failure over the year before entry into the registry.
• • ICD if indicated
• • PM if indicated
• • Willing and able to return for all follow-up visits
• Exclusion Criteria:
• • AL amyloid cardiomyopathy
• • Subjects who have a potentially correctible cause of heart failure (eg, Ischemic or valvular or congenital heart disease).
• • Scheduled for CABG or PCI or has undergone a CABG within 90 d or PCI within 30 d.
• • Myocardial infarction within 90 days
• • Mechanical tricuspid valve
• • Prior heart transplant
• • Chronic haemodialysis
• • Familial TTR amyloidotic cardiomyopathy with significant polyneuropathy potentially eligible for Patirisan or Inotersen17
• • Unable to provide informed consent